Table 1.
The clinicopathological characteristics of patients in the training, validation and combined cohorts
| Clinical and pathological indexes | Training cohort | Validation cohort | P | Combined cohort |
|---|---|---|---|---|
| N = 138 (%) | N = 171 (%) | N = 309 (%) | ||
| Age (y) | ||||
| ≤ 60 | 47 (34.06) | 65 (38.01) | 0.472 | 112 (36.25) |
| > 60 | 91 (65.94) | 106 (61.99) | 197 (63.75) | |
| Gender | ||||
| Male | 81 (58.70) | 90 (52.63) | 0.286 | 171 (55.34) |
| Female | 57 (41.30) | 81 (47.37) | 138 (44.66) | |
| Smoking | ||||
| No | 89 (64.49) | 133 (77.78) | 0.010 | 222 (71.84) |
| Yes | 49 (35.51) | 38 (22.22) | 87 (28.16) | |
| Alcohol use | ||||
| No | 104 (75.36) | 141 (82.46) | 0.126 | 245 (79.29) |
| Yes | 34 (24.64) | 30 (17.54) | 64 (20.71) | |
| Tumor size | ||||
| T1–T2 | 103 (74.64) | 135 (78.95) | 0.371 | 238 (77.02) |
| T3–T4 | 35 (25.36) | 36 (21.05) | 71 (22.98) | |
| Pathological grade | ||||
| I | 83 (60.14) | 95 (55.56) | 0.417 | 178 (57.61) |
| II–III | 55 (39.86) | 76 (44.44) | 131 (42.39) | |
| Cervical nodal metastasis | ||||
| N0 | 112 (81.16) | 121 (70.76) | 0.035 | 233 (75.40) |
| N+ | 26 (18.84) | 50 (29.24) | 76 (24.60) | |
| Clinical stage | ||||
| I–II | 91 (65.94) | 100 (58.48) | 0.180 | 191 (61.81) |
| III–IV | 47 (34.06) | 71 (41.52) | 118 (38.19) | |
| SII | ||||
| < 484.5 | 96 (69.57) | 105 (61.40) | 0.135 | 201 (65.05) |
| ≥ 484.5 | 42 (30.43) | 66 (38.60) | 108 (34.95) | |
| NLR | ||||
| < 2.9 | 109 (78.99) | 129 (75.44) | 0.461 | 238 (77.02) |
| ≥ 2.9 | 29 (21.01) | 42 (24.56) | 71 (22.98) | |
| PLR | ||||
| < 170.2 | 114 (82.61) | 129 (75.44) | 0.126 | 243 (78.64) |
| ≥ 170.2 | 24 (17.39) | 42 (24.56) | 66 (21.36) | |
| Median survival (months) | 48 (4–134) | 45 (4–138) | 46 (4–138) | |
The italic values in the table denotes P-values less than 0.05 with statistical significance